Galiximab Biosimilar Monoclonal Antibody (CD80) for Research

Cat No.: GMP-Bios-ab-229

Pre-Made Galiximab biosimilar, Whole mAb, Anti-CD80 Antibody: Anti-B7/BB1/B7-1/B7.1/LAB7/CD28LG/CD28LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-229-1mg 1mg 3090

Size： 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Galiximab biosimilar, Whole mAb, Anti-CD80 Antibody: Anti-B7/BB1/B7-1/B7.1/LAB7/CD28LG/CD28LG1 therapeutic antibody
INN Name Galiximab
TargetCD80
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2003
Year Recommended2004
CompaniesBiogen;Biogen Idec
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders;Non-Hodgkin's lymphoma;Psoriasis
Development Techna



About target - CD80

1. Protein T-lymphocyte activation antigen CD80

2. Gene CD80

3. Organism Homo sapiens (Human)

Function
Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation.

(Microbial infection) Acts as a receptor for adenovirus subgroup B.